Mitiglinide belongs to the
meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by
Kissei and
Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained
FDA approval.
Pharmacology
Mitiglinide is thought to stimulate
insulin secretion by closing the ATP-sensitive potassium
KATP channels in pancreatic
β cells.
^Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opinion on Pharmacotherapy. 9 (15): 2691–8.
doi:
10.1517/14656566.9.15.2691.
PMID18803455.
S2CID73318104.